BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2434895)

  • 1. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer.
    Zurawski VR; Broderick SF; Pickens P; Knapp RC; Bast RC
    Obstet Gynecol; 1987 Apr; 69(4):606-11. PubMed ID: 2434895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
    Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR
    Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experiences with CA 125, a tumor marker for malignant epithelial ovarian tumors].
    Crombach G; Zippel HH; Würz H
    Geburtshilfe Frauenheilkd; 1985 Apr; 45(4):205-12. PubMed ID: 2408962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.
    Chen DX; Schwartz PE; Li XG; Yang Z
    Obstet Gynecol; 1988 Jul; 72(1):23-7. PubMed ID: 3164105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer.
    Einhorn N; Sjövall K; Knapp RC; Hall P; Scully RE; Bast RC; Zurawski VR
    Obstet Gynecol; 1992 Jul; 80(1):14-8. PubMed ID: 1603484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer.
    Plante M; Wong GY; Nisselbaum JS; Almadrones L; Hoskins WJ; Rubin SC
    Obstet Gynecol; 1993 Jun; 81(6):989-92. PubMed ID: 8497368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses.
    Finkler NJ; Benacerraf B; Lavin PT; Wojciechowski C; Knapp RC
    Obstet Gynecol; 1988 Oct; 72(4):659-64. PubMed ID: 3047614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Ca 125 as tumor marker in ovarian carcinoma.
    Krebs HB; Goplerud DR; Kilpatrick SJ; Myers MB; Hunt A
    Obstet Gynecol; 1986 Apr; 67(4):473-7. PubMed ID: 3008052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
    Jacobs IJ; Oram DH; Bast RC
    Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring.
    Koebl H; Tatra G; Bieglmayer C
    Neoplasma; 1988; 35(2):215-20. PubMed ID: 3259680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative serum tumor-associated antigen levels in women with pelvic masses.
    Soper JT; Hunter VJ; Daly L; Tanner M; Creasman WT; Bast RC
    Obstet Gynecol; 1990 Feb; 75(2):249-54. PubMed ID: 2300353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum CA 125 levels in preoperative evaluation of pelvic masses.
    Vasilev SA; Schlaerth JB; Campeau J; Morrow CP
    Obstet Gynecol; 1988 May; 71(5):751-6. PubMed ID: 3162763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.
    Vuento MH; Stenman UH; Pirhonen JP; Mäkinen JI; Laippala PJ; Salmi TA
    Gynecol Oncol; 1997 Jan; 64(1):141-6. PubMed ID: 8995563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saliva and serum CA 125 assays for detecting malignant ovarian tumors.
    Chen DX; Schwartz PE; Li FQ
    Obstet Gynecol; 1990 Apr; 75(4):701-4. PubMed ID: 2179784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker.
    Bray KR; Koda JE; Gaur PK
    Cancer Res; 1987 Nov; 47(22):5853-60. PubMed ID: 2444335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum level of the tumor marker CA 125 in ovarian pathology].
    Bagni B; Pansini FS; Feggi LM; Prandini N; Mollica G
    Radiol Med; 1987 Nov; 74(5):448-50. PubMed ID: 3479814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyst fluid CA 125 levels in ovarian epithelial neoplasms.
    Menczer J; Ben-Baruch G; Moran O; Lipitz S
    Obstet Gynecol; 1993 Jan; 81(1):25-8. PubMed ID: 8416456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA 125 for the monitoring of ovarian carcinoma during primary therapy.
    Lavin PT; Knapp RC; Malkasian G; Whitney CW; Berek JC; Bast RC
    Obstet Gynecol; 1987 Feb; 69(2):223-7. PubMed ID: 2433652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of CA-125 tumor marker determination in patients with ovarian carcinoma].
    Miladinović D; Paunović R; Paunković N
    Jugosl Ginekol Perinatol; 1989; 29(3-4):83-5. PubMed ID: 2601371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.